Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29450286 | 1.00 | MAPT (0.46) | MAPTADORA1ALDH1A1MEN1KMT2A | |
| SCHEMBL29974438 | 0.92 | MAPT (0.44) | MAPTADORA1ALDH1A1MEN1KMT2A | |
| SCHEMBL183693 | 0.92 | MAPT (0.44) | MAPTADORA1ALDH1A1MEN1KMT2A | |
| SCHEMBL10654584 | 0.89 | MAPT (0.46) | MAPTALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL20015491 | 0.88 | MEN1 (0.44) | MAPTADORA1ALDH1A1MEN1KMT2A | |
| SCHEMBL183757 | 0.88 | MEN1 (0.44) | MAPTADORA1ALDH1A1MEN1KMT2A | |
| SCHEMBL4760227 | 0.87 | ADORA1 (0.44) | MAPTADORA1ALDH1A1MEN1KMT2A | |
| SCHEMBL22615393 | 0.87 | ADORA1 (0.44) | MAPTADORA1ALDH1A1MEN1KMT2A | |
| SCHEMBL1224464 | 0.86 | MAPT (0.48) | MAPTADORA1ALDH1A1MEN1KMT2A | |
| SCHEMBL1224468 | 0.86 | MAPT (0.48) | MAPTADORA1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 517 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113637001-A | Synthesis method of droperidol intermediate | 安康市农业科学研究院 | 2021-11-12 | — | — | CN | claimed |
| CN-106632318-B | A kind of tetrahydropyridine miazines compound and its preparation method and application | 广东环境保护工程职业学院 | 2018-07-31 | — | — | CN | claimed |
| CN-106632318-A | Tetrahydropyridopyrimidine compound, preparation method therefor and application of tetrahydropyridopyrimidine compound | 广东环境保护工程职业学院 | 2017-05-10 | — | — | CN | claimed |
| EP-4294800-B1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4705293-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12569485-B2 | SMARCA inhibitors and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260060985-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | GALECTIN SCIENCES, LLC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4514473-B1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-11-13 | — | — | US | disclosed |
| EP-4644396-A1 | TOLL-LIKE RECEPTOR INHIBITOR, AND PREPARATION THEREFOR AND APPLICATION THEREOF | Visionpharma (Nantong) Co., Ltd (CN) | 2025-11-05 | — | — | EP | disclosed |
| EP-0989993-A1 | TARTRATE SALT OF A SUBSTITUTED DIPEPTIDE AS GROWTH HORMONE SECRETAGOGUE | Pfizer Products Inc. (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-1999065488-A1 | THERAPEUTIC COMBINATIONS OF (SELECTIVE) ESTROGEN RECEPTOR MODULATORS (SERM) AND GROWTH HORMONE SECRETAGOGUES (GHS) FOR TREATING MUSCULOSKELETAL FRAILTY | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999003832-A1 | PIPERIDINE OLIGOMERS AND COMBINATORIAL LIBRARIES THEREOF | PHYTERA SYMBION APS (DK) | 1999-01-28 | — | — | WO | disclosed |
| WO-1998058948-A1 | TARTRATE SALT OF A SUBSTITUTED DIPEPTIDE AS GROWTH HORMONE SECRETAGOGUE | PFIZER PRODUCTS INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| EP-0869968-A1 | GROWTH-HORMONE SECRETAGOGUES | PFIZER INC. (US) | 1998-10-14 | — | — | EP | disclosed |
| US-5756508-A | Muscarine antagonists | MERCK & CO., INC. (US) | 1998-05-26 | — | — | US | disclosed |
| WO-1997024369-A1 | GROWTH-HORMONE SECRETAGOGUES | PFIZER INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997016192-A1 | MUSCARINE ANTAGONISTS | MERCK & CO., INC. (US) | 1997-05-09 | — | — | WO | disclosed |
| US-5376666-A | Hypotensive agents, angiotension antagonist, enzyme inhibitors , treating congestive heart failure | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060985-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | LGALS3, LGALS1, LGALS2 | MAPT 2059/4885ADORA1 3891/4885ALDH1A1 1833/4885 |
| US-12569485-B2 | SMARCA inhibitors and uses thereof | SMARCC1, SMARCC2, SMARCA2 | MAPT 4757/4885ADORA1 2743/4885ALDH1A1 3410/4885 |
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | WRN, RECQL, BLM | MAPT 4614/4885ADORA1 2537/4885ALDH1A1 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.